ANL

Adlai Nortye Group Ltd.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$10.52

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %14.9 / %30

Non-compliant assets / Total market cap %9.5 / %30

Non-compliant revenue / Total income %2.3 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Website

Analysis (Turkish): ANL Hissesi Caiz mi, Helal mi? Adlai Nortye Group Ltd. Katılım Analizi